JAK2 and acute myeloid leukemia: HEL cells are more malignant, being derived from erythroleukemia, have rapid proliferation and intrinsic resistance to JAK2 inhibitors20, while SET2 cells are derived from an AML secondary to ET, which have a lower proliferation rate and sensitivity to JAK2 inhibitors.21